fbpx Skip to main content

TUESDAY, Feb. 9, 2021 (HealthDay News) — Prediabetes may not be a robust diagnostic criteria for predicting diabetes progression among older adults, according to a study published online Feb. 8 in JAMA Internal Medicine.

Mary R. Rooney, Ph.D., M.P.H., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues used data from the Atherosclerosis Risk in Communities Study (baseline, 2011 to 2013) to identify 3,412 older adults (mean age, 75.6 years) without diabetes with follow-up through 2017. Different prediabetes definitions were assessed to characterize the risk for progression.

The researchers found that during the 6.5-year follow-up period, there were 156 incident total diabetes cases and 434 deaths. Forty-four percent of participants met prediabetes criteria using glycated hemoglobin (HbA1c) levels of 5.7 to 6.4 percent, while 59 percent met impaired fasting glucose (IFG) criteria (fasting glucose level of 100 to 125 mg/dL). Overall, nearly three-quarters (73 percent) met the HbA1c or IFG criteria, while 29 percent met both the HbA1c and IFG criteria. Among participants with HbA1c-defined prediabetes at baseline, 9 percent progressed to diabetes, 13 percent regressed to normoglycemia (HbA1c <5.7 percent), and 19 percent died. Of those with IFG-defined prediabetes at baseline, 8 percent progressed to diabetes, 44 percent regressed to normoglycemia (fasting glucose level of <100 mg/dL), and 16 percent died. Of those with HbA1c levels <5.7 percent at baseline, 17 percent progressed to HbA1c-defined prediabetes and 3 percent developed diabetes. Of those with fasting glucose levels <100 mg/dL at baseline, 8 percent progressed to IFG-defined prediabetes and 3 percent developed diabetes.

“In this community-based cohort study of older adults, the prevalence of prediabetes was high; however, during the study period, regression to normoglycemia or death was more frequent than progression to diabetes,” the authors write. “These findings suggest that prediabetes may not be a robust diagnostic entity in older age.”

Abstract/Full Text (subscription or payment may be required)

You May Also Like::  Lack of Sleep Tied to Physician Burnout, Medical Errors

Editorial (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More